
EpiSwitch® PSE Report

Personalized Immune Health 3D-Genetic Profile



The **EpiSwitch Prostate Screening (PSE) Test** result indicates a **high likelihood of prostate cancer.** This result is consistent with cancer being confirmed in more than 9 out of 10 men.

Your healthcare provider will consider this result along with other clinical features and history to determine which additional diagnostic test(s), such as a biopsy, is appropriate to confirm.

Patient Informatio	n	
Gender	Male	
Medical Record #	c14456d0	
Report #	PSE0254	
Previous PSA test result (ng/mL)	3.0	
Physician Release		
Physician Name	Christopher Smith, MD, MS	
Facility Name	XXX-XXX-XXX	
Address	[Address line] [City], [State] [Zip]	
Phone	811-555-4210	
Account Ref	FL	
Specimen Information		
Report Date	28-FEB-2023	
Receipt Date	28-FEB-2023	
Collection Date	20-FEB-2023	
Specimen Type	WB EDTA K3	
Specimen ID	D000097422	

EpiSwitch Prostate Screening Description

Intended Use: EpiSwitch Prostate Screening (PSE) Test is a blood-based screening test for prostate cancer that evaluates the PSA score plus a targeted PCR evaluation of five (5) DNA regulatory markers called chromatin-conformation signatures (CCS). The PSE test accurately predicts the presence or absence of prostate cancer; the significance, stage, and/or grade of the cancer will be determined from the biopsy. This information is valuable in determining who should proceed to biopsy and who can be placed on active surveillance without additional testing.

References

- 1. Pchejetski, D., et al. (2023). Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection. Cancers, 15(3), 821. http://dx.doi.org/10.3390/cancers15030821
- 2. Ishaker, H., et al. (2021). Chromatin conformation changes in peripheral blood can detect prostate cancer and stratify disease risk groups. Journal of Translational Medicine, 19(1). https://doi.org/10.1186/s12967-021-02710-y

Disclaimer: The EpiSwitch Prostate Screening (PSE) Test is a laboratory developed test (LDT). It has not been reviewed or cleared by the US Food and Drug Administration. The laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing. Decisions regarding patient care and treatment should not be solely based on a single test such as this test, rather, on the independent medical judgment of the treating physician taking into consideration all available information concerning the patient's conditions, including other clinical tests, in accordance with the standard of care in each healthcare setting.

This test was performed at Oxford BioDynamics, Inc., 7495 New Horizon Way, Frederick MD 21703 - CLIA # 21D2284653 For questions about the report, email PSE.TEST@myOBDX.com or call 1.888.236.8896

EpiSwitch® PSE Report

Personalized Immune Health 3D-Genetic Profile

Peterson, James 22-DEC-1975

EpiSwitch PSE Profile

Your Result

Low Likelihood High Likelihood

The **EpiSwitch Prostate Screening (PSE) Test** score indicates a **low likelihood of prostate cancer.** This result is consistent with the absence of cancer in more than 9 out of 10 men.

Your healthcare provider will consider this result along with other clinical features and history to determine an appropriate course of action, including active surveillance.

Patient Informatio	n	
Gender	Male	
Medical Record #	c14456d0	
Report #	PSE0254	
Previous PSA test result (ng/mL)	3.0	
Physician Release		
Physician Name	Christopher Smith, MD, MS	
Facility Name	XXX-XXX-XXX	
Address	[Address line] [City], [State] [Zip]	
Phone	811-555-4210	
Account Ref	FL	
Specimen Information		
Report Date	28-FEB-2023	
Receipt Date	28-FEB-2023	
Collection Date	20-FEB-2023	
Specimen Type	WB EDTA K3	
Specimen ID	D000097422	

EpiSwitch Prostate Screening Description

Intended Use: EpiSwitch Prostate Screening (PSE) Test is a blood-based screening test for prostate cancer that evaluates the PSA score plus a targeted PCR evaluation of five (5) DNA regulatory markers called chromatin-conformation signatures (CCS). The PSE test accurately predicts the presence or absence of prostate cancer; the significance, stage, and/or grade of the cancer will be determined from the biopsy. This information is valuable in determining who should proceed to biopsy and who can be placed on active surveillance without additional testing.

References

- 1. Pchejetski, D., et al. (2023). Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection. Cancers, 15(3), 821. http://dx.doi.org/10.3390/cancers15030821
- 2. Ishaker, H., et al. (2021). Chromatin conformation changes in peripheral blood can detect prostate cancer and stratify disease risk groups. Journal of Translational Medicine, 19(1). https://doi.org/10.1186/s12967-021-02710-y

Disclaimer: The EpiSwitch Prostate Screening (PSE) Test is a laboratory developed test (LDT). It has not been reviewed or cleared by the US Food and Drug Administration. The laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing. Decisions regarding patient care and treatment should not be solely based on a single test such as this test, rather, on the independent medical judgment of the treating physician taking into consideration all available information concerning the patient's conditions, including other clinical tests, in accordance with the standard of care in each healthcare setting.

This test was performed at Oxford BioDynamics, Inc., 7495 New Horizon Way, Frederick MD 21703 - CLIA # 21D2284653 For questions about the report, email PSE.TEST@myOBDX.com or call 1.888.236.8896